B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV

Polvere, Jacopo; Fabbiani, Massimiliano; Pastore, Gabiria; Rancan, Ilaria; Rossetti, Barbara; Zirpoli, Sara; Morelli, Eleonora; Pettini, Elena; Lucchesi, Simone; Fiorino, Fabio; Tumbarello, Mario; Ciabattini, Annalisa; Montagnani, Francesca; Medaglini, Donata

doi:10.1038/s43856-023-00245-5

Cited by 13 publications

(12 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such HIV-associated alterations of B-cell maturation may explain findings by Hwa et al showing that the antibody response in the second wave of SARS-CoV-2 infections was affected by HIV status, with PWH mounting less effective IgG responses to the Beta variant [ 72 ]. Of note, comparable alterations in the phenotype of SARS-CoV-2-specific B cells in PWH compared to heathy controls have also been observed after SARS-CoV-2 mRNA vaccination [ 84 ]…”

Section: Immune Response To Sars-cov-2 Infection In Pwhmentioning

confidence: 98%

The immune response to SARS-CoV-2 in people with HIV

Höft,

Burgers,

Riou

2023

Cell Mol Immunol

View full text Add to dashboard Cite

This review examines the intersection of the HIV and SARS-CoV-2 pandemics. People with HIV (PWH) are a heterogeneous group that differ in their degree of immune suppression, immune reconstitution, and viral control. While COVID-19 in those with well-controlled HIV infection poses no greater risk than that for HIV-uninfected individuals, people with advanced HIV disease are more vulnerable to poor COVID-19 outcomes. COVID-19 vaccines are effective and well tolerated in the majority of PWH, though reduced vaccine efficacy, breakthrough infections and faster waning of vaccine effectiveness have been demonstrated in PWH. This is likely a result of suboptimal humoral and cellular immune responses after vaccination. People with advanced HIV may also experience prolonged infection that may give rise to new epidemiologically significant variants, but initiation or resumption of antiretroviral therapy (ART) can effectively clear persistent infection. COVID-19 vaccine guidelines reflect these increased risks and recommend prioritization for vaccination and additional booster doses for PWH who are moderately to severely immunocompromised. We recommend continued research and monitoring of PWH with SARS-CoV-2 infection, especially in areas with a high HIV burden.

show abstract

Section: Immune Response To Sars-cov-2 Infection In Pwhmentioning

confidence: 98%

The immune response to SARS-CoV-2 in people with HIV

Höft,

Burgers,

Riou

2023

Cell Mol Immunol

View full text Add to dashboard Cite

show abstract

“…Another 13 studies were further removed for failing to report seroconversion (n = 6), cross-sectional studies (n = 5), reviews (n = 2) (File S1). Finally, 50 studies with a total of 7160 patients living with HIV were included in our meta-analysis 11 , 12 , 17 – 64 , 30 studies were included for qualitative analysis of serological antibody titers (Supplementary Tables S3 – S5 ); 46 studies 11 , 12 , 17 – 25 , 27 – 32 , 34 – 39 , 41 – 56 , 58 – 64 were included for quantitative analysis of pooled seroconversion rate; 34 studies 11 , 12 , 17 – 20 , 23 – 25 , 27 , 31 , 35 , 36 , 38 , 39 , 41 – 46 , 48 – 51 , 53 , 55 , 56 , 59 – 64 were used for quantitative analysis of pooled risk ratios for seroconversion following the uncomplete, complete, or booster dose of COVID-19 vaccines between patients living with HIV and HIV-negative vaccine counterparts (Fig. 1 ).…”

Section: Resultsmentioning

confidence: 99%

Serological response following COVID-19 vaccines in patients living with HIV: a dose–response meta-analysis

Zhou

Zeng

Meng

et al. 2023

Sci Rep

View full text Add to dashboard Cite

To quantify the pooled rate and risk ratio of seroconversion following the uncomplete, complete, or booster dose of COVID-19 vaccines in patients living with HIV. PubMed, Embase and Cochrane library were searched for eligible studies to perform a systematic review and meta-analysis based on PRIMSA guidelines. The pooled rate and risk ratio of seroconversion were assessed using the Freeman-Tukey double arcsine method and Mantel–Haenszel approach, respectively. Random-effects model was preferentially used as the primary approach to pool results across studies. A total of 50 studies involving 7160 patients living with HIV were analyzed. We demonstrated that only 75.0% (56.4% to 89.9%) patients living with HIV achieved a seroconversion after uncomplete vaccination, which improved to 89.3% (84.2% to 93.5%) after complete vaccination, and 98.4% (94.8% to 100%) after booster vaccination. The seroconversion rates were significantly lower compared to controls at all the stages, while the risk ratios for uncomplete, complete, and booster vaccination were 0.87 (0.77 to 0.99), 0.95 (0.92 to 0.98), and 0.97 (0.94 to 0.99), respectively. We concluded that vaccine doses were associated with consistently improved rates and risk ratios of seroconversion in patients living with HIV, highlighting the significance of booster vaccination for patients living with HIV.

show abstract

“…Of course, this may be attributed to the fact that the included studies were mRNA vaccine-related. Polvere et al ( 79 ) demonstrated that the second vaccination of mRNA vaccine elicits B-cell responses that are quantitatively similar between PLWH and HC, but there are important differences in terms of antibody functionality and phenotypes of memory B cells. More evidence is needed to support changes in B-cell antibody function in PLWH after booster vaccination with COVID-19.…”

Section: Discussionmentioning

confidence: 99%

Immunogenicity and effectiveness of COVID-19 booster vaccination among people living with HIV: a systematic review and meta-analysis

Cheng,

Li,

Weng

et al. 2023

Front. Med.

View full text Add to dashboard Cite

BackgroundThe effect of booster vaccinations with the coronavirus virus disease (COVID-19) vaccine on people living with HIV (PLWH) remains unknown. In this study, we aimed to investigate the immunogenicity and effectiveness of booster doses of the COVID-19 vaccine in PLWH.MethodsLiterature research was done through the PubMed, Embase, Cochrane Review, and Web of Science databases up to 4 July 2023. Pooled estimates were calculated and compared using the DerSimonian and Laird method for a random effects model. Randomized control trials and observational studies were both considered for inclusion.ResultsWe included 35 eligible studies covering 30,154 PLWH. The pooled immune response rate (IRR) of PLWH after the COVID-19 booster vaccination was 97.25% (95% confidence interval [CI], 93.81–99.49), and similar to healthy control (HC) (risk ratio [RR] = 0.98, 95% CI, 0.96–1.00). The pooled IRR for PLWH with CD4+ T-cell counts ≤ 200 was 86.27 (95% CI, 65.35–99.07). For Omicron variants, the pooled IRR for PLWH after booster dose was 74.07% (95% CI, 58.83–89.30), and the risk of IRR was reduced by 10% in PLWH compared with HC (RR = 0.90, 95% CI, 0.80–1.00). The T-cell immune response of PLWH was found to be comparable to HC (p ≥ 0.05). Subgroup analyses revealed that mRNA vaccines produced a relatively high IRR in PLWH compared to other vaccines. In addition, the results showed that booster vaccination appeared to further reduce the risk of COVID-19-related infections, hospitalizations, and deaths compared with the primary vaccination.ConclusionIt was shown that booster vaccination with the COVID-19 vaccine provided a high IRR in PLWH and still produced a desirable moderate IRR in PLWH with a CD4+ T-cell count of ≤ 200. Importantly, the humoral and T-cell responses to booster vaccination in PLWH were comparable to HC, and similar results were observed with the SARS-CoV-2 Omicron variant. Our review strongly emphasizes the effect of mRNA vaccine booster vaccination in PLWH on eliciting desirable protective IRR. Furthermore, booster vaccination appears to further reduce the risk of COVID-19 infection, hospitalization, and death in PLWH compared to primary vaccination. However, more evidence is needed to confirm its effectiveness.

show abstract

B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV

Cited by 13 publications

References 49 publications

The immune response to SARS-CoV-2 in people with HIV

The immune response to SARS-CoV-2 in people with HIV

Serological response following COVID-19 vaccines in patients living with HIV: a dose–response meta-analysis

Immunogenicity and effectiveness of COVID-19 booster vaccination among people living with HIV: a systematic review and meta-analysis

Contact Info

Product

Resources

About